No insider purchase over the last 90 days. The latest, by Gaslightwala Abizer, was filed 29 Aug 2025.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2025 · cache
25 of 71 declarations
At Akari Therapeutics PLC, grants dominate: 55 of the 71 filings published between April 30, 2024 and October 16, 2026, with 9 option exercises and 7 purchases, but no sale. The 7 purchases, all by Abizer Gaslightwala, Chief Executive Officer, total EUR 49,056 with a median of EUR 6,407. The three largest date from 2025: EUR 15,676 on June 17, EUR 10,423 on June 20 and EUR 8,094 on August 21.
Abizer Gaslightwala is the most frequent filer, with 19 filings; Samir Rashmikant Patel, a director, signs 16, Kameel D. Farag, Interim CFO, 12, and Raymond Prudo-Chlebosz and Sandip I. Patel, directors, 5 each, with no purchase or sale.
The pace rises year after year: 16 filings in 2024, 26 in 2025 and 29 in 2026. The last twelve months hold 32 filings, with no purchase or sale. This US health care company, listed on Nasdaq, is valued at USD 21.2 million, and insiders hold 14.4% of it. The median publication delay is 3 days.
Insider filings
Over the last 90 days, 19 filings published between 5 August and 16 October 2026: no open-market purchase or sale filed by an insider. 19 other filings (not open-market purchases or sales: grants, options, plans, sale notices, block transfers).
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 22 October 2026 (UTC)
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | n.d. | -17.3 m USD | 0.00 USD | 10-K |
| Dec 2024 | n.d. | -19.8 m USD | 0.00 USD | 10-K |
| Dec 2023 | n.d. | -10.0 m USD | 0.00 USD | 10-K |
| Dec 2022 | n.d. | -17.7 m USD | 0.00 USD | 10-K |
| Dec 2021 | n.d. | -17.4 m USD | 0.00 USD | 20-F |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.